Company News 
Corporate Activities 
Industry News 
Contact: Mr Gerry
Tel: 86-21-61900721
                  61900733
Fax: 86-21-61900735
Mobile: 86-13636696795
E-mail: sales@run-biotech.com
Website: www.run-biotech.com

New Breast Cancer Drug Approved by FDA
Shanghai Run-Biotech Co.,Ltd.   2013-04-12 00:11:48 Author:SystemMaster Source:WebMD News from HealthDa Font size:[Large][Middle][Small]

A new drug for late-stage breast cancer has been approved by the U.S. Food and Drug Administration.

Genentech's Kadcyla (ado-trastuzumab emtansine) is for use in patients with HER2-positive, late-stage breast cancer who were previously treated with another anti-HER2 drug called Herceptin (trastuzmab) and a class of chemotherapy drugs called taxanes, which are commonly used to treat breast cancer.

"Kadcyla is trastuzumab connected to a drug called DM1 that interferes with cancer cell growth," Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in an FDA news relase.

"Kadcyla delivers the drug to the cancer site to shrink the tumor, slow disease progression and prolong survival. It is the fourth approved drug that targets the HER2 protein," he explained.

The FDA's approval of the drug was based on a study of 991 patients. Kadcyla carries a boxed warning that it can cause liver and heart problems and even death. It can also cause life-threatening birth defects, the agency said.

About us Projects Services News Client Support
Our Team
R & D Capabilities
Enterprise Culture
 

Pharmaceutical Discovery
bio-pharmaceuticals
Biological Reagents
Analysis & Separation
Natural Healthcare
Standard Sample
Process Development
Preclinical Research

 
Company News
Corporate Activities
Industry News
 
Download
Login
Feedback
Contact us
Job

Shanghai Run-Biotech Co.,Ltd. Copyright © 2013